Mustafa ÖZYURT, Tuğrul HOŞBUL, Bayhan BEKTÖRE, Barış YALÇIN, Mehmet Burak SELEK

Investigation of linezolid resistance in Staphylococcus epidermidis: first reported linezolid resistant coagulase negative staphylococcus in Turkey*

PDF

___

1. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251 3255.
2. Laursen BS, Sørensen HP, Mortensen KK, Sperling-Petersen HU. Initiation of protein synthesis in bacteria. Microbiol Mol Biol Rev 2005; 69: 101123.
3. Livermore DM. Linezolid in vitro mechanism and antibacterial spectrum. J Antimicrob Chemother 2003; 51: ii9ii16.
4. Kloss PL, Xiong DL, Mankin AS. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294: 93101.
5. Wong A, Reddy SP, Smyth DS, Aguero-Rosenfeld ME, Sakoulas G, Robinson DA. Polyphyletic emergence of linezolid-resistant Staphylococci in the United States. Antimicrob Agents Chemother 2010; 54: 742748.
6. Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 2006; 50: 25002505.
7. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing, Approved standard M100-S20. 20th edition. Wayne, PA, USA; 2010.
8. Hong T, Xiangyang L, Wang J, Sloan C, Cicogna C. Sequential linezolid-resistant Staphylococcus epidermidis isolates with G2576T mutation. J Clin Microbiol 2007; 45: 32773280.
9. Vardakas KZ, Kioumis I, Falagas ME. Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome. Curr Drug Metab 2009; 10: 212.
10. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8: 5366.
11. Stefani S, Bongiorno D, Mongelli G, Campanile F. Linezolid resistance in Staphylococci. Pharmaceuticals 2010; 19882006.
12. Afşar I, Barış I, Şener AG, Köksal V, Demirci M. Linezolidresistant Enterococcus faecium: the first G2576T mutation in Turkey. Mikrobiyol Bul 2012; 46: 516518.
13. Baos E, Candel FJ, Merino P, Pena I, Picazzo JJ. Characterization and monitoring of linezolid-resistant clinical isolates of Staphylococcus epidermidis in an intensive care unit 4 years after an outbreak of infection by cfr-mediated linezolidresistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2013; 76: 325329.
14. Ağalar C, Göçmen JS, Kılıç D, Kaygusuz S, Karabıçak Ç. Üçüncü basamak bir referans hastanesinde izole edilen metisilin dirençli stafilokok suşlarında duyarlılık. J Clin Exp Invest 2012; 3: 7174 (in Turkish).
15. Öksüz L, Gürler N. Susceptibility of clinical methicillinresistant Staphylococci isolates to new antibiotics. J Infect Dev Ctries 2013; 7: 825831.
16. Polacek N, Mankin AS. The ribosomal peptidyl transferase center: structure, function, evolution, inhibition. Crit Rev Biochem Mol Biol 2005; 40: 285311.
17. Aoki HL, Poppe SM, Poel TJ, Weaver EA, Gadwood RC, Thomas RC, Shinabarger DL, Ganoza MC. Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes. Antimicrob Agents Chemother 2002; 46: 10801085.
18. Mitchell P, Stade K, Osswald M, Brimacombe R. Site-directed cross-linking studies on the E. coli tRNA-ribosome complex: determination of sites labelled with an aromatic azide attached to the variable loop or aminoacyl group of tRNA. Nucleic Acids Res 1993; 21: 887896.
19. Rinke-Appel J, Jünke N, Osswald M, Brimacombe R. The ribosomal environment of tRNA: crosslinks to rRNA from positions 8 and 20:1 in the central fold of tRNA located at the A, P, or E site. RNA 1995; 1: 10181028.